Synthetic peptides: Managing lipid disorders

Current Opinion in Lipidology

Volumn 17, Issue 3, 2006, Pages 233-237

  Anantharamaiah, G M ^a,c   Navab, Mohamad ^b,c   Reddy, Srinivasa T ^b,c   Garber, David W ^a   Datta, Geeta ^a   Gupta, Himanshu ^a   White, C Roger ^a   Handattu, Shaila P ^a   Palgunachari, Mayakonda N ^a   Chaddha, Manjula ^a   Mishra, Vinod K ^a   Segrest, Jere P ^a   Fogelman, Alan M ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UAB Medical Center ^*  (United States)

Author keywords

Apolipoprotein mimetic peptides; Apolipoproteins; Atherosclerosis; Lipid disorders; Lipoproteins

Indexed keywords

ACETYLASPARTYLLYSYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYL PHENYLALANYLGLUTAMYLTRYPTOPHANYLALANYLLYSYLGLUTAMYLALANYLPHENYLALANYLAMIDE; APOLIPOPROTEIN; ASPARTYLLYSYLTRYPTOPHANYLLYSYLALANYLVALYLTYROSYLASPARTYLLYSYLPHENYLALANYL ALANYLGLUTAMYLALANYLPHENYLALANYLLYSYLGLUTAMYLPHENYLALANYLLEUCYLAMIDE; CHOLESTEROL; PEPTIDE DERIVATIVE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG ACTIVITY; DRUG BIOAVAILABILITY; LIPID TRANSPORT; MOLECULAR MODEL; NONHUMAN; PEPTIDE SYNTHESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SOLUBILITY;

ANIMALS; CHRONIC DISEASE; HUMANS; LIPID METABOLISM, INBORN ERRORS; PEPTIDES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33646883084     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000226114.89812.75     Document Type: Review

References (32)

1. Anantharamaiah GM, Jones JL, Brouillette CG, et al. Studies of synthetic peptide analogs of amphipathic helix I: structure of peptide/DMPC complexes. J Biol Chem 1985; 260:10248-10255.
2. Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. Methods Enzymol 1986; 128:627-647.
3. Yancey PG, Bielicki JK, Lund-Katz S, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995; 34:7955-7965.
4. Venkatachalapathi YV, Phillips MC, Epand RM, et al. Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins Structure Function Genet 1993; 15:349-359.
5. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001; 42:1096-1104.
6. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331. This review article chronicles the development of class A amphipathic mimetic peptides.
7. Palgunachari MN, Mishra VK, Lund-Katz S, et al. Only the two end helixes of eight tandem amphipathic helical domains of apoA-I have significant lipid affinity. Arterioscler Thromb Vascular Biol 1996; 16:328-338.
8. Epand RM, Epand RF, Sayer BG, et al. An apolipoprotein Al mimetic peptide: Membrane interactions and the role of cholesterol. Biochemistry 2004; 43:5073-5083.
9. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42:545-552.
10. Datta G, Epand RF, Epand RM, et al. Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity. J Biol Chem 2004; 279:26509-26517.
11. Epand RM, Epand RF, Sayer BG, et al. Two homologous apolipoprotein Al mimetic peptides: relationship between membrane interactions and biological activity. J Biol Chem 2004; 279:51404-51414.
12. Reddy ST, Anantharamaiah GM, Navab M, et al. Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 2006; 15:13-21. This is a useful review.
13. Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res 2006; 47:107-114.
14. Mishra VK, Anantharamaiah GM, Segrest JP, et al. Association of a model class A (apolipoprotein) amphipathic alpha-helical peptide with lipid: high resolution NMR studies of peptide-lipid discoidal complexes. J Biol Chem 2006; 9 January [Epub ahead of print].
15. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290-292.
16. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002; 106:1127-1132.
17. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004; 110:3252-3258.
18. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353:9-11. This is an excellent review of oxidized phospholipids.
19. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353:46-57.
20. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
21. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
22. Li X, Chyu KY, Faria Neto JR, et al. Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110:1701-1705.
23. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005; 15:291-296. This is an outstanding review.
24. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1426-1432. This article demonstrates that an oral synthetic amphipathic peptide can induce regression of established lesions.
25. Ou Z, Ou J, Ackerman AW, et al. L-4F, an apolipoprotein mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003; 107:1520-1524.
26. Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107:2337-2341.
27. Ou J, Wang J, Xu H, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double knockout mice on Western diet. Circ Res 2005; 97:1190-1197. This article highlights the role of apoA-I in the functioning of apoA-I mimetic peptides.
28. Navab M, Anantharamaiah GM, Fogelman AM. An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-I. Circ Res 2005; 97:1085-1086.
29. Kruger AL, Peterson S, Turkseven S, et al. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 2005; 111:3126-3134. This is an outstanding example of the mechanism of action and potential therapeutic application of synthetic amphipathic peptides in diabetes.
30. Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1932-1937. This article demonstrates that a G* amphipathic helical peptide is also effective in an animal model of dyslipidemia and atherosclerosis.
31. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral small peptides render HDL anti-inflammatory in mice and monkeys and reduce atherosclerosis in apoE null mice. Circ Res 2005; 97:524-532. This article demonstrates that synthetic peptides as small as tetrapeptides may have therapeutic potential.
32. Gupta H, White CR, Handattu S, et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circ Res 2005; 111:3112-3118. This article demonstrates a synthetic peptide that lowers plasma apoB-containing lipoproteins and improves vascular reactivity in an animal model of familial hypercholesterolemia.